ImmunoMet Therapeutics

ImmunoMet Therapeutics is a private, clinical-stage biotech focused on targeting cellular metabolism for novel anti-cancer and anti-fibrosis therapies. The company's core platform involves inhibiting oxidative phosphorylation (OxPhos) via protein complex 1 (PC1) inhibitors, with its lead candidate, lixumistat, currently in Phase 1b trials for pancreatic cancer. Founded as a spin-off from HanAll Biopharma, ImmunoMet has raised $39 million to date and is advancing a library of biguanide compounds. Its interim leadership and scientific advisory boards bring decades of pharmaceutical R&D experience to the venture.

Platform of biguanide small molecules targeting oxidative phosphorylation (OxPhos) by inhibiting mitochondrial Protein Complex I (PC1) to disrupt energy metabolism in cancer and fibrotic cells.

ImmunoMet operates in the emerging field of cancer metabolism, competing with other companies developing OXPHOS and mitochondrial inhibitors. Its specific focus on biguanide-based PC1 inhibitors differentiates it, but it must demonstrate superior efficacy or safety to established and novel therapies in competitive indications like pancreatic cancer.